$ELTP We will Launch Next Year.... Lawsuit is settled... Thanks God...
Irrevocable Covenant Not to Market: Elite Laboratories entered into an irrevocable covenant promising not to market its generic extended-release oxycodone hydrochloride products (under ANDA No. 217939) in the United States until Purdue’s asserted patents officially expire on August 24, 2027.Paragraph III certification. This change legally states that Elite will not seek final FDA approval until the patents expire.
$ELTP
This is Over We Win..... Its in the Report..... Waiting on News....
The Dispute: Purdue Pharma filed a patent infringement lawsuit against Elite Laboratories (a subsidiary of Elite Pharmaceuticals). The case is an Abbreviated New Drug Application (ANDA) patent suit, which typically occurs when a generic manufacturer attempts to launch a generic version of a branded drug before its patents expire.
$ELTP If the best this stock will ever do is $1, for the amount of revenue they have , it’s still a joke . Perhaps getting out and saying goodbye between 50 and 80 cents is the new exit strategy!!
$ELTP going to be a big spike today, maybe even 0.50. Not saying it will hold forever, but any amount of volume through this ticker shoots it up and down like crazy.
$ELTP Elite should see a nice move higher today and into tomorrow as analysts and headline readers digest how good Elite is now performing; growing Revenues, Profits, Cash, and pipeline.
💊💰💊💰💊
$SPY @LieutenantJoe 👀
$ELTP
From CHATGPT:
A company growing revenue at 100% year over year changes the picture significantly.
For a generic drug company:
100% YoY growth is rare. Most generic drug businesses grow in the low single digits or teens because the market is mature and highly competitive.
If that growth is sustainable (not just from one acquisition or a one-time product launch), investors may be willing to pay a much higher revenue multiple.
A rough framework:
1–3× sales: Mature, slow-growth generic companies.
4–7× sales: Strong growth, improving margins, or differentiated products.
8–12× sales: Possible if the market believes the company can continue growing near 100%, expand margins, and eventually generate substantial earnings.
15×+ sales: Usually reserved for biotech or software-like growth businesses, not traditional generics.
Using today's revenue base, that implies roughly:
Conservative: $0.60–$0.80/share
Bull case: $0.90–$1.30/share
Very aggressive: $1.50+
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Valuation
Trading at NaN× earnings vs its 6.1× historical median P/E.
Fair value ≈ $-0.10 · price $0.40 today
Fair value · 0% above
Loading valuation…
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
